...
首页> 外文期刊>Oncoimmunology. >Sperm associated antigen 9 (SPAG9) expression and humoral response in benign and malignant salivary gland tumors
【24h】

Sperm associated antigen 9 (SPAG9) expression and humoral response in benign and malignant salivary gland tumors

机译:涎腺良性和恶性肿瘤中精子相关抗原9(SPAG9)的表达和体液反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Salivary gland cancers are highly aggressive epithelial tumor associated with metastatic potential and high mortality. The tumors are biologically diverse and are of various histotypes. Besides, the detection and diagnosis is a major problem of salivary gland cancer for available treatment modalities. In the present study, we have investigated the association of sperm associated antigen 9 (SPAG9) expression with salivary gland tumor (SGT). Clinical specimens of benign (n = 16) and malignant tumors (n = 86) were examined for the SPAG9 expression. In addition, the sera and adjacent non-cancerous tissues (n = 72) from available patients were obtained. Our in situ RNA hybridization and immunohistochemistry (IHC) analysis revealed significant difference (p D 0.0001) in SPAG9 gene and protein expression in benign (63%) and malignant tumor (84%) specimens. Further, significant association was also observed between SPAG9 expression and malignant tumors (P = 0.05). A cut-off value of >10% cells expressing SPAG9 protein designated as positive in IHC, predicted presence of malignant SGT with 83.72% sensitivity, 100% specificity, 100% PPV and 83.72% NPV. Humoral response against SPAG9 protein was generated in 68% of SGT patients. A cut-off value of 0.212 OD for anti-SPAG9 antibodies in ELISA predicted presence of malignant SGT with 69.23% sensitivity, 100% specificity, 100% PPV and 78.94% NPV. Collectively, our data suggests that the majority of SGT show significant difference and association among benign and malignant tumors for SPAG9 gene and protein expression and also exhibit humoral response against SPAG9 protein. Hence, SPAG9 may be developed as a biomarker for detection and diagnosis of salivary gland tumors.
机译:唾液腺癌是高度侵袭性的上皮肿瘤,具有转移潜力和高死亡率。肿瘤在生物学上是多样的,并且具有各种组织类型。此外,对于可用的治疗方式,检测和诊断是唾液腺癌的主要问题。在本研究中,我们研究了精子相关抗原9(SPAG9)表达与涎腺肿瘤(SGT)的关系。检查SPAG9表达的临床标本(n = 16)和恶性肿瘤(n = 86)。另外,从可获得的患者中获得了血清和邻近的非癌组织(n = 72)。我们的原位RNA杂交和免疫组织化学(IHC)分析显示,良性(63%)和恶性肿瘤(84%)标本中SPAG9基因和蛋白质表达存在显着差异(p D 0.0001)。此外,还观察到SPAG9表达与恶性肿瘤之间的显着相关性(P = 0.05)。在IHC中,> 10%的表达SPAG9蛋白的细胞的临界值被确定为阳性,预测恶性SGT的存在具有83.72%的敏感性,100%的特异性,100%的PPV和83.72%的NPV。 68%的SGT患者产生了针对SPAG9蛋白的体液反应。 ELISA中抗SPAG9抗体的截止值为0.212 OD,可预测恶性SGT的存在,灵敏度为69.23%,特异性为100%,PPV为100%,NPV为78.94%。总体而言,我们的数据表明,大多数SGT在SPAG9基因和蛋白质表达的良性和恶性肿瘤之间显示出显着差异和关联,并且还表现出针对SPAG9蛋白质的体液反应。因此,SPAG9可以被开发为用于唾液腺肿瘤的检测和诊断的生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号